Combining medical information (MI) and pharmacovigilance (PV) has been shown to drive an array of positive outcomes, including accelerating adverse event intake, improving healthcare professional and patient communications, intelligently connecting enterprise systems and importantly, driving better patient safety. New innovations in connected technologies are finally making it possible to combine elements of these functions in a thoughtful way. However, the change from legacy processes and mindset will be significant and driving employee adoption to see the benefit of these investments will require careful change management. IQVIA’s Annette Williams and Libbie McKenzie explore considerations for leaders looking to combine aspects of their MI and PV functions and how they can effectively roll out this shift to maximize the benefits to their organizations along with patients, providers, and other key stakeholders.
EVERSANA and ArisGlobal announced a strategic partnership to digitally transform end-to-end pharmacovigilance services, leading to safer and more effective healthcare for patients worldwide.
Dr. Reddy’s Laboratories’ Foram Vaishnav discusses the role and impact of pharmacovigilance in the pharmaceutical industry.
If you are a clinical researcher or scientist, you are well-aware of the inefficiencies of current search processes that require hours of time wading through data to find hidden nuggets of valuable info.
Habit and red tape are not sufficient excuses for life sciences organizations to keep doing things the way they always have.
UK Biopharma and life after BrexitBiomedicine, Brexit, Business, EMA, EU, European Economic Area, European Free Trade Association (EFTA), Life Sciences, Marketing Authorization Application (MAA), Medical Devices, National Institute for Health and Care Excellence (NICE), Orphan Drug Designation, Personalized Medicine, Pharma, Pharmacovigilance, Pricing, R&D, Switzerland, United Kingdom, World Trade Organisation (WTO)
Paul Ranson, of global law firm Morgan Lewis’ London Life Science’s Practice, examines how the UK Biopharma must now adapt to a changing landscape.
ALEXANDRIA, Va., Aug. 27, 2015 /PRNewswire-USNewswire/ — The Academy of Managed Care Pharmacy (AMCP) is disappointed in the Food and Drug Administration’s (FDA’s) draft guidance and proposed rule that calls for biologics, […]
Safety platform upgrade delivers more reporting power and greater flexibility and support for worldwide regulatory requirements DIA 2015 — WASHINGTON DC — June 16, 2015 — Oracle Health Sciences […]